GPC1 and non-small cell lung carcinoma: This finding offers new insight into the molecular response to anti-GPC1 mAb treatment in NSCLC, providing a rational basis for a combination strategy that incorporates a GPC1 inhibitor to sensitize tumors to certain targeted therapeutics.